Part 6/9:
Despite the alluring prospects, investing in Chinese biotech isn’t without its pitfalls. The first major concern revolves around the corporate structures of Chinese companies. Foreign investors often encounter a complex landscape wherein ownership of direct equity isn't straightforward. American Depository Shares (ADS) are the primary means of investing, but these structures can pose inherent risks if the Chinese government decides to alter existing agreements.